State-of-the-art chemotherapy for advanced breast cancer

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 9, 2000, Pages 3-12

  Piccart, M J ^a   Awada, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; 9 NITROCAMPTOTHECIN; ANTHRACYCLINE; ANTIMETABOLITE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PREDNISOLONE; TAXANE DERIVATIVE; TAXOL; TAXOTERE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ALGORITHM; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; MONOTHERAPY; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTHRACYCLINE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEOXYCYTIDINE; HUMAN; PACLITAXEL; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T;

EID: 0033781241     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. The third generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
2. The role of taxanes in the treatment of breast cancer
3. Paclitaxel (Taxol)
4. Docetaxel: A new defense in the management of breast cancer
5. Breast cancer therapies in development. A review of their pharmacology and clinical potential
6. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
7. Docetaxel versus mitomycin C plus vinblastine in anthracycline-resistant metastatic breast cancer
8. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
9. Tamoxifen for early breast cancer: An overview of the randomised trials
10. Polychemotherapy for early breast cancer: An overview of the randomised trials
11. Ovarian ablation in early breast cancer: Overview of the randomised trials
12. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
13. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The 'Philadelphia' Intergroup Study
14. Paclitaxel pharmacokinetics and pharmacodynamics
15. Docetaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer
16. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
17. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
18. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B- 26
19. Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with met breast cancer. The long and short of it
20. A population pharmacokinetic model for docetaxel (taxotere): Model building and validation
21. Paclitaxel via 1-hour infusion: Rationale and pharmacology
22. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer
23. Weekly docetaxel in patients with advanced refractory malignancies: A phase I trial
24. Activity of weekly Taxotere in patients with metastatic breast cancer
25. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
26. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with crossover
27. A prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
28. Doxorubicin/Taxol versus doxorubicin/cyclophosphamide as first line chemotherapy in metastatic breast cancer: A phase III study
29. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for MBC
30. Taxotere versus methotrexate-5 fluorouracil in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavia Breast Cancer Group
31. Phase III study: Taxotere versus 5-fluorouracil + Navelbine in patients with metastatic breast cancer as 2nd line chemotherapy (preliminary results)
32. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
33. Multicenter phase II study of capecitabine in paclitalxel-refractory metastatic breast cancer
34. A randomized phase II study of Xeloda (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥55 years
35. A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
36. Phase II trial of UFT activity in pretreated breast cancer patients
37. Oral tegafur in the treatment of metastatic breast cancer: A phase II study
38. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials
39. A phase II open label study to evaluate a 28-day oral regimen of 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with taxane and anthracycline resistant advanced breast disease: Preliminary results
40. A phase II study in advanced breast cancer: ZD1694 (Tomudex) a novel direct and specific thymidylate synthase inhibitor
41. Phase II study of LY231514 (MTA) in patients with locally recurrent or metastatic breast cancer (LR/MBC) - An interim report
42. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study
43. Phase II study of edatrexate in chemotherapy naive patients with metastatic breast cancer
44. Phase II study of gemcitabine in patients with metastatic breast cancer
45. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens
46. Advanced breast cancer: A phase II trial with gemcitabine
47. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
48. Doxil in patients with pretreated metastatic breast cancer (MBC): A dose-schedule finding study with pharmacokinetics
49. EORTC 10968: Phase I study of Caelyx at six-week interval in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium
50. Oral idarubicin in advanced breast cancer patients with low-risk prognostic factors
51. Phase II study of losoxantrone in previously treated and untreated patients with advanced breast cancer
52. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
53. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study
54. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
55. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer
56. Clinical and laboratory studies of topotecan in breast cancer
57. A phase II study of topotecan on a daily X 5 schedule as second-line single agent therapy in patients with advanced breast cancer
58. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients
59. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer
60. A phase II study of oral topotecan as single agent, third-line therapy in women with metastatic breast cancer
61. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: Current status and future prospects
62. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
63. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-Her2 monoclonal antibody Herceptin in Her2-overexpressing metastatic breast cancer
64. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
65. Inhibitors of tyrosine kinase
66. Inhibitors of prenyl transferases
67. New strategies of interest in the management of breast cancer